Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human hepatocyte growth factor naked plasmid injection in CLI (Rutherford 5) patients
CTR20190750Phase 3Completed
- Sponsor
- Northland Biotech
- Start
- Apr 2019
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of naked plasmid encoding human hepatocyte growth factor in chronic limb-threatening ischemia (CLTI), arteriosclerosis obliterans, sponsored by Northland Biotech. Started Apr 2019; status: completed.
02
Drugs
naked plasmid encoding human hepatocyte growth factor
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20190750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190750.